• Ainsi, l'essai LATITUDE-TIMI 60 (The Losmapimod To Inhibit P38 MAP Kinase As A Therapeutic Target And Modify Outcomes After An Acute Coronary Syndrome), qui évalue le losmapimod, un inhibiteur de MAP-kinase (Mitogen-activated protein kinase), dans le syndrome coronarien aigu. (medscape.com)